日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy

痰液中结核分枝杆菌mRNA作为抗结核治疗后细菌清除的标志物

Li, L; Mahan, C S; Palaci, M; Horter, L; Loeffelholz, L; Johnson, J L; Dietze, R; Debanne, S M; Joloba, M L; Okwera, A; Boom, W H; Eisenach, K D

Evaluation of low-colony-number counts of Mycobacterium tuberculosis on solid media as a microbiological marker of cross-contamination

评估结核分枝杆菌在固体培养基上的低菌落数作为交叉污染的微生物学标志物

Ribeiro, F K C; Lemos, E M; Hadad, D J; Leão, S C; Viana-Niero, C; Dietze, R; Johnson, J L; Eisenach, K D; Palaci, M

Mycobacteraemia among HIV-1-infected patients in São Paulo, Brazil: 1995 to 1998

1995年至1998年巴西圣保罗HIV-1感染患者中分枝杆菌血症的发生情况

Hadad, D J; Palaci, M; Pignatari, A C C; Lewi, D S; Machado, M A S; Telles, M A S; Martins, M C; Ueki, S Y M; Vasconcelos, G M; Palhares, M C A

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

抑制异烟肼诱导的痰液中结核分枝杆菌抗原85的表达:结核病化疗试验中的潜在替代标志物

Wallis, R S; Phillips, M; Johnson, J L; Teixeira, L; Rocha, L M; Maciel, E; Rose, L; Wells, C; Palaci, M; Dietze, R; Eisenach, K; Ellner, J J

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.

利法拉嗪在肺结核患者中的安全性和杀菌活性

Dietze R, Teixeira L, Rocha L M, Palaci M, Johnson J L, Wells C, Rose L, Eisenach K, Ellner J J

Molecular epidemiology of Mycobacterium avium complex isolated from patients with and without AIDS in Brazil and England

巴西和英国艾滋病患者和非艾滋病患者分离出的鸟分枝杆菌复合群的分子流行病学研究

Telles, M A; Yates, M D; Curcio, M; Ueki, S Y; Palaci, M; Hadad, D J; Drobniewski, F A; Pozniak, A L